Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Isavuconazonium Sulfate

These articles are all highly relevant Isavuconazonium Sulfate. I believe this information can help you understand Isavuconazonium Sulfate's professional information. If you want to know more, you can contact us at any time, we can provide you with more professional guidance.
  • Drug Patent & Exclusivity Expiration Report - Week of Sep 01 2025

    Drug Patent & Exclusivity Expiration Report - Week of Sep 01 2025

    2025-09-01

    This week, there are 10 drugs in the patent and exclusivity list. They are: - SUCAMPO PHARMA AMERICAS LLC's AMITIZA, containing active ingredient LUBIPROSTONE - GENENTECH INC's ERIVEDGE, containing active ingredient VISMODEGIB - GE HEALTHCARE's VIZAMYL, containing active ingredient FLUTEMETAMOL F-18 - AVERITAS PHARMA INC's QUTENZA, containing active ingredient CAPSAICIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's PRADAXA, containing active ingredient DABIGATRAN ETEXILATE MESYLATE - BAYER HEALTHCARE PHARMACEUTICALS INC's KERENDIA, containing active ingredient FINERENONE - VERTEX PHARMACEUTICALS INC's ORKAMBI, containing active ingredient IVACAFTOR; LUMACAFTOR - CURIUM US LLC's DETECTNET, containing active ingredient COPPER CU-64 DOTATATE - RIGEL PHARMACEUTICALS INC's GAVRETO, containing active ingredient PRALSETINIB - ASTELLAS PHARMA US INC's CRESEMBA, containing active ingredient ISAVUCONAZONIUM SULFATE Read More